$KROS News

Keros Therapeutics, Inc. (KROS) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Keros Therapeutics Announces Participation at Goldman Sachs 47th Annual Global Healthcare Conference

KROS Turns to Next Wave of TGF-Beta Muscle Therapies

Should You Buy KROS After Q1 Miss and Takeda Deal Reset?

KROS Stock Guide to Rinvatercept in DMD and ALS for 2026

Earnings Release: Here's Why Analysts Cut Their Keros Therapeutics, Inc. (NASDAQ:KROS) Price Target To US$21.20

Keros Therapeutics, Inc. (KROS) Reports Q1 Loss, Misses Revenue Estimates

Keros Therapeutics Reports Recent First Quarter 2026 Financial Results

Keros Therapeutics Q1 EPS $(1.21) Misses $(1.02) Estimate, Sales $367.000K Miss $583.333K Estimate

Aytu BioPharma, Inc. (AYTU) Reports Q3 Loss, Tops Revenue Estimates

Enanta Pharmaceuticals (ENTA) Reports Q2 Loss, Lags Revenue Estimates

KROS Pipeline Catalysts: DMD Phase II and ALS Plans for 2026

KROS Stock: What to Know About Rinvatercept in DMD

KROS: Is the Discount Book Value a Value Trap?

Keros Therapeutics Announces Collaboration with Sean M. Healey & AMG Center for ALS

Keros Therapeutics Presents Additional Clinical Data from Its Rinvatercept Program at the 2026 MDA Clinical & Scientific Conference

Keros Therapeutics Presents Additional Data From Its Phase 1 Clinical Study Of Rinvatercept In Health Volunteers At 2026 Muscular Dystrophy Association Clinical & Scientific Conference

Can Keros Therapeutics Rinvatercept Stand Out in the DMD Market?

Keros Therapeutics shares are trading lower after the company reported worse-than-expected Q4 financial results. Also, Wells Fargo lowered its price target on the stock from $23 to $20.

Keros Therapeutics shares are trading lower after the company reported worse-than-expected Q4 financial results. Also, Wells Fargo lowered its price target on the stock from $23 to $20.